Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fadrozole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 known ✓ | P11511 | 15/20 | 1.00 |
| ▸ | CYP11B2 | P19099 | 9/20 | 0.97 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fadrozole SCHEMBL9739941 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| Dexfadrostat SCHEMBL4619633 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| Fadrozole SCHEMBL4143 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| Dexfadrostat SCHEMBL685516 | 0.99 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| S-Fadrozole SCHEMBL13449014 | 0.99 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| Fadrozole SCHEMBL25491 | 0.99 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| Fadrozole SCHEMBL3295820 | 0.99 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| Fadrozole SCHEMBL1650121 | 0.96 | CYP19A1 (0.95) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL2351202 | 0.95 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| Hydrochloric Acid SCHEMBL9836543 | 0.92 | CYP19A1 (1.00) | CYP19A1CYP11B2CYP11B1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 250 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080138437-A1 | Antitumor Agent | KABUSHIKI KAISHA SANGI (JP) | 2008-06-12 | — | — | US | claimed |
| EP-1719527-A1 | ANTITUMOR AGENT | KABUSHIKI KAISHA SANGI (JP) | 2006-11-08 | — | — | EP | claimed |
| US-5098911-A | Enzyme inhibitors and antiestrogens, storage stability | CIBA-GEIGY CORPORATION (US) | 1992-03-24 | — | — | US | claimed |
| US-12630510-B2 | EP2 antagonist | ONO PHARMACEUTICAL CO., LTD. (JP) | 2026-05-19 | — | — | US | disclosed |
| EP-4714467-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING CANCER | ISM Co., Ltd. (JP) | 2026-03-25 | — | — | EP | disclosed |
| US-12497377-B2 | Tricyclic spiro compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-12-16 | — | — | US | disclosed |
| US-12486504-B2 | Drug delivery composition, method for producing same and use thereof | Yamamoto, Hirofumi (JP) | 2025-12-02 | — | — | US | disclosed |
| US-20250288554-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR NON-ALCOHOLIC STEATOHEPATITIS-DERIVED HEPATOCARCINOMA | SEAKNIT BIOLOGICAL TECHNOLOGY CO., LTD. (CN) | 2025-09-18 | — | — | US | disclosed |
| EP-3992176-B1 | EP2 ANTAGONIST | ONO PHARMACEUTICAL CO (JP) | 2025-08-27 | — | — | EP | disclosed |
| US-20250197401-A1 | PURINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-06-19 | — | — | US | disclosed |
| CN-119707932-A | Ethanesulfonic acid salts of quinoline derivatives | 小野药品工业株式会社 | 2025-03-28 | — | — | CN | disclosed |
| US-6753310-B1 | ANGIOGENESIS-SPECIFIC PEPTIDES; DRUG DELIVERY; ANTICARCINOGENIC AGENTS; CANCER DIAGNOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-22 | — | — | US | disclosed |
| US-20030165576-A1 | Antitumor effect potentiators | MITSUBISHI PHARMA CORPORATION (JP) | 2003-09-04 | — | — | US | disclosed |
| US-20030092754-A1 | External preparation for skin diseases containing nitroimidazole | SHOEI CO., LTD. (JP) | 2003-05-15 | — | — | US | disclosed |
| EP-1295607-A1 | ANTITUMOR EFFECT POTENTIATORS | Mitsubishi Pharma Corporation (JP) | 2003-03-26 | — | — | EP | disclosed |
| EP-1206937-A1 | NITROIMIDAZOLE EXTERNAL PREPARATIONS FOR DERMATOSIS | SHOEI CO., LTD. (JP) | 2002-05-22 | — | — | EP | disclosed |
| EP-1122262-A1 | NEOVASCULAR-SPECIFIC PEPTIDES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-08 | — | — | EP | disclosed |
| US-6083916-A | Pharmaceutical product for application to uterus mucosa | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-07-04 | — | — | US | disclosed |
| EP-0873751-A2 | Pharmaceutical product for application to uterus mucosa | TAKEDA CHEMICAL INDUSTRIES, Ltd. (JP) | 1998-10-28 | — | — | EP | disclosed |
| US-5098911-A | Enzyme inhibitors and antiestrogens, storage stability | CIBA-GEIGY CORPORATION (US) | 1992-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630510-B2 | EP2 antagonist | PTGER2, PTGER1, PTGER4 | CYP19A1 1513/4885CYP11B2 70/4885CYP11B1 178/4885 |
| US-20250197401-A1 | PURINONE DERIVATIVE | BTK, KIT, SYK | CYP19A1 592/4885CYP11B2 400/4885CYP11B1 157/4885 |
| US-20250288554-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR NON-ALCOHOLIC STEATOHEPATITIS-DERIVED HEPATOCARCINOMA | FABP1, SLC10A1, HDGF | CYP19A1 3096/4885CYP11B2 2384/4885CYP11B1 2603/4885 |
| US-20030165576-A1 | Antitumor effect potentiators | RHOT2, ROCK2, CIT | CYP19A1 4556/4885CYP11B2 3362/4885CYP11B1 3742/4885 |
| US-12497377-B2 | Tricyclic spiro compound | PTGER4, PTGER1, PTGER3 | CYP19A1 756/4885CYP11B2 114/4885CYP11B1 124/4885 |
| US-20030092754-A1 | External preparation for skin diseases containing nitroimidazole | IL4I1, NSD1, CUTA | CYP19A1 1398/4885CYP11B2 416/4885CYP11B1 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.